Integrative Metabolomic and Proteomic Signatures Define Clinical Outcomes in Severe COVID-19

Sergio Alvarez-Mulett[1]*, Mustafa Buyukozkan[2,3]*, Alexandra C. Racanelli[1]*, Frank Schmidt[4], Richa Batra[2,3], Katherine L. Hoffman[5], Hina Sarwath[4], Rudolf Engelke[4], Luis Gomez-Escobar[1], Will Simmons[5], Elisa Benedetti[2,3], Kelsey Chetnik[2,3], Edward Schenck[1], Karsten Suhre[4], Justin J. Choi[6], Zhen Zhao[7], Sabrina Racine-Brzostek[7], He S. Yang[7], Mary E. Choi[8], Augustine M.K. Choi[1], Soo Jung Cho[1#], Jan Krumsiek[2,3#]

[1]Department of Medicine, Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New York, NY, USA

[2]Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA

[3]Meyer Cancer Center and Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA

[4]Department of Biochemistry, Weill Cornell Medicine – Qatar, Qatar Foundation, Doha, Qatar

[5]Department of Population Health Sciences, Division of Biostatistics, Weill Cornell Medicine, New York, NY, USA

[6]Department of Medicine, Division of General Internal Medicine, Weill Cornell Medicine, New York, NY, USA

[7]Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA

[8]Division of Nephrology and Hypertension, Joan and Sanford I. Weill Department of Medicine, New York, NY, USA

* these authors contributed equally to this work

[#] corresponding authors

Correspondence to:

Jan Krumsiek, jak2042@med.cornell.edu

Soo Jung Cho, sjc9006@med.cornell.edu

Abstract

The novel coronavirus disease-19 (COVID-19) pandemic caused by SARS-CoV-2 has ravaged global healthcare with previously unseen levels of morbidity and mortality. To date, methods to predict the clinical course, which ranges from the asymptomatic carrier to the critically ill patient in devastating multi-system organ failure, have yet to be identified. In this study, we performed large-scale integrative multi-omics analyses of serum obtained from COVID-19 patients with the goal of uncovering novel pathogenic complexities of this disease and identifying molecular signatures that predict clinical outcomes. We assembled a novel network of protein-metabolite interactions in COVID-19 patients through targeted metabolomic and proteomic profiling of serum samples in 330 COVID-19 patients compared to 97 non-COVID, hospitalized controls. Our network identified distinct protein-metabolite cross talk related to immune modulation, energy and nucleotide metabolism, vascular homeostasis, and collagen catabolism. Additionally, our data linked multiple proteins and metabolites to clinical indices associated with long-term mortality and morbidity, such as acute kidney injury. Finally, we developed a novel composite outcome measure for COVID-19 disease severity and created a clinical prediction model using a set of 33 metabolites. The model significantly improved the identification of key events of critical illness such as prolonged hospitalization, supplemental oxygen requirement, acute kidney injury (AKI), and acute respiratory distress syndrome (ARDS), beyond those achieved using the more traditional risk factors of age, gender, and BMI.

Introduction

The novel coronavirus disease 2019 (COVID-19) has a broad spectrum of clinical features that range from asymptomatic disease to acute respiratory distress syndrome (ARDS)(1, 2). COVID-19 ARDS can lead to refractory hypoxia, mechanical ventilation, prolonged intensive care unit (ICU) stay and increased mortality(3). Previous studies have shown a high incidence of concomitant organ failure in COVID-19, including acute kidney injury (AKI)(4), acute liver injury(5), thromboembolic events(6, 7) and secondary infections contributing to a fatal outcome(8).

Massive investigative efforts by multiple scientific groups have used proteomic and
metabolomic approaches to begin to unravel disease mechanisms relevant to SARS-
CoV-2 infection such as inflammation, coagulation, and metabolism(9). However, how
COVID-19 specific protein-metabolite interactions relate to the severity of disease and
clinical outcomes remains poorly understood. Key study limitations have included
relatively small sample sizes, absence of protein-metabolite network analysis and the
focus on dichotomous outcome measures such as death and survival. These limitations
have been difficult to overcome and restrict our understanding of COVID-19
pathogenesis.

Here, we report the largest study to integrate metabolomic and proteomic analyses of
serum samples obtained from hospitalized COVID-19 patients during SARS-CoV-2
infection compared to controls during the same time period as controls (Figure 1).
Through this work, we uncovered COVID-19-specific metabolite and protein profiles,
identified novel protein-metabolite modules, and defined the molecular signatures of
several clinical indices (CRP, ferritin, platelet count, AKI, and death). Additionally, we
developed the first clinical composite outcome prediction model in COVID-19, where the
input of discrete metabolic profiles significantly improves our clinical insight into a broad
range of outcomes known to plague many survivors of severe COVID-19.

Results

Study cohort and dataset

Our cohort was comprised of 330 patients with confirmed SARS-CoV-2 RT-PCR, and 97
non-COVID-19 controls with negative RT-PCR results who were hospitalized at the
NewYork-Presbyterian Hospital/Weill Cornell Medical Center between March and April
2020. Serum samples were obtained within the first 3 days of admission. The majority of
COVID-19 patients had samples drawn at two or three different time points resulting in a
total of 582 serum samples from the 330 COVID-19 patients, while all 97 controls had
one sample drawn. A detailed description of the clinical and demographic characteristics
of the cohort can be found in Table 1 and Supplementary Table 1. Of note, we excluded
samples collected after intubation because we found that the clinical act of intubation
significantly alters a patient's metabolic profile (Supplementary Table 2).

Metabolic profiles were assessed for all samples using liquid chromatography coupled
with mass spectrometry (LC/MS). After quality control and data preprocessing, 125
metabolites were available for comparative analysis. Proteomic profiling was performed
on a subset of 227 samples (173 from COVID-19 patients and 54 controls) using the Olink
inflammation, cardiovascular II and cardiovascular III panels, which cover 266 unique
protein biomarkers.

Metabolomic and proteomic changes associated with COVID-19
Differential metabolomic analysis identified significant changes in abundances of 70 out
of the 125 analyzed metabolites between COVID-19 and controls at a false discovery rate
(FDR) of 0.05 (Figure 2A). The top three differentially expressed metabolites were
involved in amino acid metabolism: N-acetyl-L-aspartic acid (p-value = 9.19E-18), N-
acetyl-aspartyl-glutamic acid (p-value = 5.30E-15), and argininosuccinic acid (p-value =
6.35E-12) (Figure 2B). KEGG pathway mapping of the differentially expressed
metabolites revealed an involvement of various metabolic pathways (Figure 2C). These
pathways included arginine and proline metabolism, glycine and serine metabolism,
alanine metabolism, methionine metabolism, sphingolipid metabolism, gluconeogenesis,
and the TCA cycle pathway, demonstrating involvement of the broader categories of
amino acid, lipid and energy metabolism in COVID-19 pathogenesis.

Comparative proteomic analysis identified significant changes in the expression of 48 out
of the 266 analyzed proteins between COVID-19 and controls at an FDR of 0.05
(Figure 2D). The top three differentially expressed proteins were C-X-C motif chemokine
ligand 10 (CXCL10) (p-value = 5.09E-13), galectin 9 (Gal-9) (p-value = 5.49E-10), and
monocyte chemoattractant protein 3 (MCP-3) (p-value = 2.85E-09) (Figure 2E). KEGG
pathway mapping revealed that these proteins participated in various protein pathways
(Figure 2F) including the interleukin 17 (IL-17), tumoral necrosis factor (TNF) and JAK-
STAT signaling pathways. Detailed results of the differential analysis and pathway
mappings can be found in Supplementary Table 3.

Protein-metabolite networks identify potential mediators of COVID-19 pathology

To obtain further mechanistic insight into the biology of COVID-19, we developed a comprehensive, data-driven network for the integrative analysis of our multi-omics dataset. We first generated a Gaussian graphical model (GGM) of correlated metabolites and proteins from our COVID-19 cohort (Figure 3A, Supplementary Data 1). GGMs are correlation-based network models that we have previously demonstrated to accurately reconstruct biological pathways from blood-based omics data(10-12). A minimum spanning tree-based algorithm was then used to identify a focused subnetwork that connects the most significantly correlated metabolites and proteins from the original network (Figure 3B). The subnetwork included 13 proteins from the Olink inflammatory panel, 32 proteins from the Olink cardiovascular panels II and III, and 70 metabolites. From this subnetwork, we selected 4 network modules to query the interplay between metabolism, inflammation, and vascular dysfunction in COVID-19 patients.

Inflammation-related network modules. Module 1. Our network identified hexanoylcarnitine as a key metabolite associated with inflammatory cytokines in COVID-19 illness. The module contained IFN-gamma, CXCL10 and CXCL11 that were all upregulated in COVID-19 and associated with hexanoylcarnitine. IFN-gamma, CXCL10 and CXCL11 are proinflammatory cytokines which regulate T cell immunity(13), while hexanoylcarnitine is a medium-chain fatty acid conjugate that plays a critical role in energy metabolism and mitochondrial fatty acid β-oxidation (Figure 3B)(14). Levels of other carnitine species (L-carnitine and caprylic acid) were also elevated in COVID-19 patients, suggesting a role for inflammation, dysregulated fatty acid β-oxidation and mitochondrial dysfunction in COVID-19 pathogenesis.

Module 2. In a second inflammation-related module, cytosine was another key metabolite linked with inflammatory cytokines during COVID-19. The module consisted of a group of macrophage-derived cytokines, including MCP-2, MCP-3 and GRN, which were all upregulated in COVID-19 and positively associated with cytosine (Figure 3B). This finding is consistent with the hyperinflammatory state of COVID-19 infection in which cytokine storm is often observed(15). Cytosine, a pyrimidine-class nucleotide that is an essential metabolite for cell proliferation and survival, is commonly upregulated in the host

response during viral infection and is furthermore an important mediator of viral
replication(16). Prior reports have shown cytosine levels to be elevated in COVID-19
patients(17), which was corroborated in our own cohort. Taken together, cytosine may be
a key metabolite linking viral replication to SARS-CoV-2 induced inflammation.

Vascular-related network modules. Module 3. While COVID-19 presents itself mainly as
a respiratory disease, autopsy reports have additionally described significant vascular
injury due to endothelial cell damage, microcirculatory thrombi, and impaired cellular
junction integrity(18). Our network uncovered the coordination of MERTK, RAGE and
thrombomodulin (TM) with the metabolite 4-hydroxyproline in COVID-19 (Figure 3B).
MERTK, RAGE and TM are proteins key to maintaining features of endothelial
homeostasis, and hydroxyproline is a major component of collagen(19). MERTK, a
member of the TAM family of receptor tyrosine kinases (RTKs), and RAGE, a pro-
coagulant and inflammatory molecule were upregulated, while TM was downregulated,
suggesting induction of a pro-coagulant and inflammatory vascular state in COVID-19.
Notably, the coordination of these proteins centered around alterations in levels of
hydroxyproline, where downregulation of TM directly correlated with hydroxyproline
levels. A link between TM and hydroxyproline has been described, where administration
of TM had anti-fibrotic effects on lung and kidney murine models(20). Taken together,
these data link the pro-coagulant and fibrotic state of COVID-19 through thrombomodulin
and hydroxyproline.

Module 4. In a second vascular-related module, we found that cathepsin D (CTSD), a
lysosomal protease known to disrupt endothelial cell junctions and increase
vasopermeability, was associated with a group of glycolytic metabolites including
D-glucose, glycerol-3-phosphate, and lactic acid(21). Notably, increased vascular
permeability and glycolysis are known features of a pro-angiogenic state(22). While
dysregulated angiogenesis occurs in COVID-19 patients(23), how these events are
coordinated remains poorly understood. Here, we report the concomitant up-regulation of
cathepsin D and intermediate products of glycolysis (D-glucose and lactic acid) in our
COVID-19 cohort, which position this enzyme as a potential driver of the COVID-19
phenotype. Of note, elevated plasma activity of cathepsin D has been found in patients

with type 2 diabetes, suggested a link between abnormal vasculature and the

dysregulated glucose metabolism seen in our higher risk diabetic COVID-19 patients(24).

Taken together these data suggest that the disruption of vascular and glucometabolic

homeostasis in COVID-19 is mediated by cathepsin D.

Serum metabolites and proteins associate with clinical indices in COVID-19

Serum metabolites and proteins within the COVID-19 patient group were assessed for

correlation with relevant clinical indices including: i) demographics (sex, age, BMI), ii)

concurrent comorbidity (hypertension, pre-existing kidney disease, diabetes mellitus

[DM], severity of illness [SOFA]), iii) laboratory markers of inflammation (C-reactive

protein [CRP], d-dimer, lymphocyte count, platelet count, ferritin), and iv) future clinical

events (ARDS, death) (Figure 4A and 4D). Pre-existing kidney disease was found to

associate with the highest number of both metabolites and proteins. Other clinical

parameters including ARDS, death, BMI, gender, age, SOFA score, hypertension, DM,

and d-dimer levels were associated with numerous metabolites but only few proteins.

Conversely, platelet count and ferritin level were associated with a large number of

proteins but relatively few metabolites. Detailed association results are provided in

Supplementary Tables 4 and 5.

Hierarchical clustering of clinical indices by their correlation with metabolites revealed two

broad clusters: one predominantly related to laboratory markers of inflammation, and a

second largely related to non-laboratory indices (Figure 4B). Volcano plots of three

representative indices (death, pre-existing kidney disease and CRP) are shown in

Figure 4C. Seventy-five metabolites were significantly associated with death, 96 with pre-

existing kidney disease and 37 with CRP level. 69 metabolites were associated with both

death and kidney disease and 20 were associated with death, kidney disease and CRP

levels. Key metabolites associated with each of the three selected clinical indices are

depicted in Figure 4C. Remarkably, hexanoylcarnitine and cytosine, which we earlier

showed to be upregulated in COVID-19, were among the 20 metabolites associated with

all three of these clinical indices. This finding supports the potential utility of

hexanoylcarnitine and cytosine not only as biomarkers for COVID-19 but also as
predictors of disease severity.

Clustering of clinical indices according to their correlation with proteins also revealed two
broad clusters (Figure 4E) that were notably similar to the metabolite-derived clusters,
except that age and kidney disease clustered together with laboratory markers of
inflammation. Volcano plots of three representative indices (death, ferritin level and
platelet count) are depicted in Figure 4F. Seventeen proteins correlated with death, 26
with platelet count and 29 with ferritin. Six proteins were associated with both death and
ferritin level, 9 with death and platelet count, and 5 (ANGPT1, PDGF subunit A, PDGF
subunit B, LAP TGF-beta-1, CXCL5) with death, ferritin level and platelet count
(Figure 4F). ANGPT1, PDGF subunit A and PDGF subunit B are markers of endothelial
injury and platelet dysfunction while LAP, TGF-beta-1 and CXCL5 are markers of
inflammation. The fact that these proteins correlated with known clinical indices of
COVID-19 mortality and morbidity corroborates the importance of vascular injury and
inflammation in COVID-19 pathogenesis, which we observed in our network analysis
above.

Metabolomics signature predicts clinical outcomes in COVID-19.
We devised a novel hierarchical composite outcome measure for COVID-19 severity
which incorporates a series of clinical events, ranked in order of severity, that characterize
both acute COVID-19 and some of the sequelae of COVID-19 seen in post-acute COVID-
19 syndrome (PACS)(25): in-hospital mortality, mechanical ventilation (MV) at discharge,
kidney replacement therapy (KRT) at discharge, prolonged organ failure support
(mechanical ventilation and/or kidney replacement therapy for more than 2 weeks),
supplemental oxygen requirement, acute kidney injury and length of hospital stay
(Figure 5A, Supplementary Figure 1). Our measure represents each patient on a
continuous spectrum of severity to provide more information than a dichotomous
classification such as mortality.

A machine learning algorithm based on an ordinal response mixed effect model with
LASSO regularization and cross-validation was used to generate our prediction model of

the composite outcome measure using serum metabolic profiles and baseline patient
demographics (age, sex and BMI) as combined inputs (Figure 5B). Proteins were not
included in the model due to insufficient sample size. The final model included 33
metabolites and achieved an average concordance-index of d=0.69 (SE=0.017, 95% CI
of [0.65, 0.72]), which is equivalent to a receiver operating characteristics area under the
curve (ROC-AUC). This was a significant improvement (p-value = 1E-5) over a baseline
model containing only age, sex, and BMI, which had a performance of d=0.59 (SD=0.02,
95% CI of [0.56, 0.64]). The 33 metabolites in the final model included 14 amino acids, 6
nucleotides, 6 lipids and 2 metabolites related to energy metabolism (Figure 5C).
Interestingly, our metabolite-based model showed improvement over the baseline model
not only for predicting the composite outcome, but also for predicting some of its individual
components (i.e., intubation, AKI, and length of hospital stay, Figure 5D).

We assessed the tradeoff between the number of metabolites incorporated into the model
and the model's prediction performance across a range of included metabolites. Our
analysis revealed that most of the predictive power (d ~ 0.68) was already achieved with
the first 6 metabolites, after which prediction performance did not significantly improve
(Supplementary Figure 2). This finding suggests that a targeted assay of a small number
of metabolites could predict disease severity with this accuracy, although independent
validation in other datasets remains to be established.

We compared our results with a model reported previously (26), which represents the
closest analysis to the one we have performed here and reported a remarkably higher
AUC of 0.95. However, several aspects prevent a direct comparison of theirs and our
performance metrics. First, our study had a substantially larger sample size with 296
patients and 487 plasma samples, compared to 31 for training and 29 for testing in Shen
et al. Second, our reported AUC was based on cross-validation and thus less likely to
overestimate the model performance, while Shen. et al only reported a training set-based
AUC. Third, our own reanalysis of the published data by Shen et al. shows that
metabolites in their model do not improve predictive performance beyond age alone
(Supplementary Figure 3), while we demonstrated a clear improvement beyond baseline.
Fourth, our model defines an ordinal classification of severity as opposed to prior studies

that have dichotomized outcomes into severe and non-severe cases which is known to

be statistically less powerful and can lead to bias(27, 28). Taken together, we believe that

our analysis provides a higher powered and a more holistic assessment of the added

value of metabolites to predict disease severity as well as the effect on overall quality of

life rather than just predicting survival.

Conclusion

The novel coronavirus has ravaged the global healthcare system due to its high

transmissibility and unpredictable clinical course that often affects multiple organ

systems. Moreover, the long-term consequences of COVID-19 infection remain poorly

understood. A full understanding of the pathogenesis of COVID-19 will require an

unraveling of the mechanisms of inflammation, immune dysfunction, endothelial cell injury

and dysregulated coagulation that underlie this disease.

In our study, we used an integrative proteomic-metabolomic analysis to identify global

molecular signatures specific to the acute illness of COVID-19, while many prior

metabolomic and proteomic studies have not assessed the interplay between proteins

and metabolites. Our analyses establish associations of specific inflammation and

vascular injury-related proteins with various metabolites during COVID-19, which appear

to link inflammation with mitochondria-dependent energy metabolism and viral replication,

as well as coagulation with fibrogenesis and glycolysis.

There is increasing evidence that evaluating symptoms and multiple clinical outcomes

during acute disease is crucial in determining the risk of long COVID-19(29). To the best

of our knowledge, we are the first group to develop a composite outcome measure in

COVID-19 using multiple clinical indices in a prediction model that assesses not only

COVID-19 disease severity but also the sequelae of COVID-19 that characterize post-

acute COVID-19 syndrome (PACS). Compared to dichotomous outcome measures such

as death and survival, our composite outcome score reflects a broader, more holistic

assessment of COVID-19 morbidity in the hospital setting.

Several key strengths underlie our study cohort. As opposed to the use of healthy controls

reported in other COVID-19 studies(9, 26, 30-32), our use of non-COVID patient samples,

in the same hospital during the same time period between March and April 2020, allowed

us to investigate the interactions highly relevant to COVID-19 pathogenesis and clinical

course. We furthermore had relatively large sample sizes compared to other studies, with

hundreds of samples available for both metabolomic and proteomic analysis.

Our study has several limitations. As alterations in proteome and metabolome were

analyzed in sera but not in lung tissues or bronchoalveolar lavage fluid, our results may

not reflect what occurs at tissue-specific cellular levels. Furthermore, based on the current

study design and methodology, the correlative relationships we report between

metabolomic and proteomic alterations and SARS-CoV-2 outcomes should be interpreted

as purely correlative rather than causal in nature. Additional studies are required to define

the mechanistic roles of individual molecules highlighted in this paper. Finally, as our

study was only a single center investigation, our results will need to be validated in other

cohorts.

In conclusion, our investigation has sought to not only define the metabolomic and

proteomic signatures of COVID-19, but also to explore interactions between metabolites

and proteins that can serve as a roadmap for future mechanistic studies. We have

furthermore proposed a novel clinical composite outcome score that can be used in a

clinical prediction model for COVID-19. Ultimately, a better understanding of the

pathophysiology of COVID-19 at the molecular level may lead to short-term and long-

term targeted therapies.

Methods

Cohort description

This is a single-center prospective analysis of one cohort comparing hospitalized COVID-

19 patients and non-COVID-19 controls. Our cohort was comprised of 330 patients with

confirmed SARS-CoV-2 RT-PCR, and 97 non-COVID-19 controls with negative RT-PCR

results who were hospitalized at the NewYork-Presbyterian Hospital/Weill Cornell

Medical Center between March and April 2020. This study has been approved by the

Weill Cornell Medicine (WCM) IRB with protocol #19-10020914. Remnant serum samples

were matched with selected patients after which patients were deidentified. Hospitalized

controls were selected based on the results of RT-PCR for SARS-CoV-2 reported as

negative, and then they were matched the samples with selected patients. Children (less

than 18 years old) and pregnant women (confirmed by a positive beta-HCG test and/or

medical records) were excluded.

Sample handling

Standard practices for serum collection and storage at the NewYork-Presbyterian/Weill

Cornell Medical College include collecting venous blood into a serum-separating tube

(SST), and serum is obtained by centrifuging at 1,500g for 7 minutes as soon as possible

with a maximum time limit of 2 hours from the time of collection. The specimens are

typically stored at 4°C for 1 to 5 days before coded/de-identified and then transferred into

a -80°C freezer. Samples were thawed and inactivated in different ways: for the

metabolomic analysis, x3 sample volume of HPLC grade ethanol were added; for the

proteomic analysis, the samples were heat-inactivated in a water bath of 56°C for 15

minutes. After these processes, the samples were stored again at -80°C until the analyses

were performed.

Data Collection

Data were obtained from the Weill Cornell Medicine COVID Institutional Data Repository

(COVID-IDR), which is a high-quality registry of COVID-19 patients at NewYork-

Presbyterian - Cornell with laboratory confirmed SARS-CoV-2 RT-PCR. The COVID-IDR

houses both manually and automatically extracted Electronic Health Record (EHR) data.

Demographics, comorbidities, and important dates of patients' hospital course

(admission, intubation, extubation, discharge, death) were extracted by a team of medical

professionals and stored in the COVID-IDR. Laboratory tests, ventilation parameters, vital

signs, and respiratory variables were additionally available via automated extraction

through the Weill Cornell-Critical Care Database for Advanced Research (WC-CEDAR)

within the COVID-IDR. WC-CEDAR(33) is a critical care database originally designed to

automatically extract, transform, and store EHR data on Intensive Care Unit (ICU)

patients; it was expanded to include all hospitalized patients during New York City's
COVID-19 surge. Data not available within WC-CEDAR were manually extracted and
recorded in REDCap.
362

Metabolomic profiling

Metabolite profiling was performed according to methods described in a previous
publication(34). In brief, metabolites were extracted using pre-cooled 80% methanol and
measured on a Q Exactive Orbitrap mass spectrometer (Thermo Scientific), which was
coupled to a Vanquish UPLC system (Thermo Scientific) via an Ion Max source and HESI
II probe (Thermo Scientific). The Q Exactive was operated in full scan, polarity-switching
mode. A Sequant ZIC-HILIC column (2.1 mm i.d. × 150 mm, Merck) was used for
separation of metabolites. Flow rate was set at 150µL/min. Buffers consisted of 100%
acetonitrile for mobile phase A, and 0.1% NH4OH/20 mM CH3COONH4 in water for
mobile phase B. Gradient ran from 85% to 30% A in 20 min followed by a wash with 30%
A and re-equilibration at 85% A. Metabolites were identified based on exact mass within
5ppm and standard retention times.
375

Proteomic profiling

Proteomics analysis was performed using the Olink platform (Uppsala, Sweden) at the
Proteomics Core of Weill Cornell Medicine-Qatar, according to manufacturer's
instructions. We used the Inflammation, Cardiovascular II and Cardiovascular III panels.
High throughput real-time PCR of reporter DNA lined to protein specific antibodies was
performed on a 96-well integrated fluidic circuits chip (Fluidigm, San Francisco, CA). Each
sample was spiked with quality controls to monitor the incubation, extension, and
detection steps of the assay. Additionally, samples representing external, negative, and
inter-plate controls were included in each analysis run. From raw data, real time PCR
cycle threshold (Ct) values were extracted using Fluidigm reverse transcription
polymerase chain reaction (RT-PCR) analysis software at a quality threshold of 0.5 and
linear baseline correction. Ct values were further processed using the Olink NPX manager
software (Olink, Uppsala, Sweden). Here, log2-transformed Ct values from each sample
and analyte were normalized based on spiked-in extension controls and scale-inverted to

obtain Normalized log2-scaled Protein Expression (NPX) values. NPX values were
adjusted based on the median of inter plate controls (IPC) for each protein and intensity
median scaled between all samples and plates.

Each metabolite and protein was annotated with pathways from the Kyoto Encyclopedia
of Genes and Genomes (KEGG) database(35).

Data preprocessing

Children, pregnant women, and samples after intubation were excluded from all analyses.

The metabolomics data was measured in three different batches. For each batch, data
was preprocessed by filtering out samples with more than 50% missing values, followed
by filtering out metabolites with more than 25% missing values, probabilistic quotient
normalization(36), and log2 transformation. Two extreme outlier metabolites were
manually removed (phosphorylcholine and adenosine monophosphate). The next step
was to merge the different batches into a joint dataset. Batch 3 contained only control
patients and could thus not be simply added by batch correction. Instead, batches 2 and
3 contained an overlapping set of samples which were used for an anchor-based
normalization by dividing each metabolite in batch 3 by the mean fold change of the
overlapping samples. The anchor samples from batch 3 were then deleted and the
batches combined using median-based batch correction(37). Missing values were then
imputed using the k-nearest neighbor approach(37).

Proteomics data preprocessing included the same steps of filtering, quotient
normalization, logging, and missing value imputation with identical parameters as for the
metabolomics data. Ten proteins were measured as duplicates on the Olink platform, so
their expression values were averaged.

Statistical analysis

416 Differential expression of metabolites and proteins for both the COVID-19 vs. control
417 analysis as well as the clinical parameter analysis within the COVID-19 cohort was
418 assessed using the following linear mixed effect model:

419   *met_prot ~ outcome + time + (1|patient),*

where *met_prot* is each individual metabolite or protein, *outcome* is either COVID-19

yes/no or the value of a clinical parameter, *time* is the day of sample taking as a factor,

and *(1|patient)* is a random effect per patient to account for repeated measurements.

P-values are reported for the significance of the outcome term.

Data preprocessing and statistical analysis was performed using the "maplet" toolbox for

R(38) (https://github.com/krumsieklab/maplet).

Network construction

Network construction

The dataset was first reduced to the samples that overlap between metabolomics and

proteomics, and corrected for age, sex, BMI, and COVID-19 status (yes/no). A Gaussian

Graphical Model (GGM) based network was then constructed using the GeneNet

algorithm(39) and drawing an edge for all partial correlations with an FDR smaller than

0.2. In a second step, this network was condensed to highlight the connections between

molecules that were significantly different between COVID-19 and controls. To this end,

a shortest-path distance matrix between all molecules was constructed and subset to the

significant molecules. A minimum spanning tree(40) of this matrix was then constructed

to visualize a simplified network.

Composite Outcome

438 **Composite Outcome**

439 A detailed description of the construction of the composite outcome can be found in

440 Supplementary Figure 1.

Regularized linear mixed effect ordinal regression model

Regularized linear mixed effect ordinal regression model

A new regression model was developed to deal with an ordinal outcome, repeated

measurements, and feature selection with regularization. Repeated measurements are

handled as a random effect, while age, sex, BMI, and metabolites are treated as fixed

effects. The metabolites are penalized using an L_1 LASSO-type regularization to obtain a

sparse solution. The model is fitted using an mixed-effect ordinal regression model with

complementary log-log link function(41), using maximum likelihood (ML) estimation as

proposed by Ripatti and Pamgren(42). An optimal LASSO penalty parameter was

estimated through an iterative algorithm for maximizing the Laplace approximation of the
integrated model likelihood. This approach was adapted from Therneau(43), which was
originally developed for mixed effect Cox models. To obtain an unbiased estimate of the
model performance, leave-one-out-cross-validation across the entire dataset was
performed. The added value of metabolomics data over baseline clinical data was
assessed by comparing the final model with a model only consisting of age, sex, and BMI.
455

Data Availability
There are legal and ethical restrictions on data sharing because the Institutional Review
Board of Weill Cornell Medicine did not approve public data deposition. The data set used
for this study constitutes sensitive patient information extracted from the electronic health
record. Accordingly, it is subject to federal legislation that limits our ability to disclose it to
the public, even after it has been subjected to deidentification techniques. To request the
access of the de-identified minimal dataset underlying these findings, interested and
qualified researchers should contact Information Technologies & Services Department of
Weill Cornell Medicine support@med.cornell.edu.
465

466 **Code Availability**
467 Code to reproduce all the statistical results presented in this paper is available at
468 https://github.com/krumsieklab/covid-omics.
469

Funding
JK is supported by the National Institute of Aging of the National Institutes of Health under
award 1U19AG063744. SJC is supported by National Heart, Lung and Blood Institute
under award K08HL138285. KS is supported by 'Biomedical Research Program' funds at
Weill Cornell Medical College in Qatar, a program funded by the Qatar Foundation and
multiple grants from the Qatar National Research Fund (QNRF).

References

1.   Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20.

2.   Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. N Engl J Med. 2020;382(22):2081-90.

3.   Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054-62.

4.   Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98(1):209-18.

5.   Zhang C, Shi L, Wang F-S. Liver injury in COVID-19: management and challenges. The Lancet Gastroenterology & Hepatology. 2020;5(5):428-30.

6.   Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. JAMA. 2020.

7.   Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-7.

8.   Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, et al. Causes of death and comorbidities in hospitalized patients with COVID-19. Scientific Reports. 2021;11(1):4263.

9.   Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584(7821):463-9.

10.   Krumsiek J, Suhre K, Illig T, Adamski J, Theis FJ. Gaussian graphical modeling reconstructs pathway reactions from high-throughput metabolomics data. BMC Syst Biol. 2011;5:21.

11.   Krumsiek J, Suhre K, Evans AM, Mitchell MW, Mohney RP, Milburn MV, et al. Mining the unknown: a systems approach to metabolite identification combining genetic and metabolic information. PLoS Genet. 2012;8(10):e1003005.

12.   Benedetti E, Pučić-Baković M, Keser T, Wahl A, Hassinen A, Yang JY, et al. Network inference from glycoproteomics data reveals new reactions in the IgG glycosylation pathway. Nat Commun. 2017;8(1):1483.

13.   Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat Rev. 2018;63:40-7.

14.   Stanley CA, Hale DE, Berry GT, Deleeuw S, Boxer J, Bonnefont J-P. A Deficiency of Carnitine–Acylcarnitine Translocase in the Inner Mitochondrial Membrane. New England Journal of Medicine. 1992;327(1):19-23.

15.   McGonagle D, Ramanan AV, Bridgewood C. Immune cartography of macrophage activation syndrome in the COVID-19 era. Nature Reviews Rheumatology. 2021;17(3):145-57.

16.   Hoelzer K, Shackelton LA, Parrish CR. Presence and role of cytosine methylation in DNA viruses of animals. Nucleic acids research. 2008;36(9):2825-37.

17.   Liu M, O'Connor RS, Trefely S, Graham K, Snyder NW, Beatty GL. Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47−mediated 'don't-eat-me' signal. Nature Immunology. 2019;20(3):265-75.

18.   Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. The Lancet. 2020;395(10234):1417-8.

19.   Xu S, Gu M, Wu K, Li G. Unraveling the Role of Hydroxyproline in Maintaining the
Thermal Stability of the Collagen Triple Helix Structure Using Simulation. The Journal of
Physical Chemistry B. 2019;123(36):7754-63.
20.   Takeshita A, Yasuma T, Nishihama K, D'Alessandro-Gabazza CN, Toda M, Totoki T, et
al. Thrombomodulin ameliorates transforming growth factor-β1–mediated chronic kidney
disease via the G-protein coupled receptor 15/Akt signal pathway. Kidney International.
2020;98(5):1179-92.
21.   Monickaraj F, McGuire P, Das A. Cathepsin D plays a role in endothelial–pericyte
interactions during alteration of the blood–retinal barrier in diabetic retinopathy. The FASEB
Journal. 2018;32(5):2539-48.
22.   Leung SWS, Shi Y. The glycolytic process in endothelial cells and its implications. Acta
Pharmacologica Sinica. 2021.
23.   Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al.
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. New England
Journal of Medicine. 2020;383(2):120-8.
24.   Chen J, Wu C, Wang X, Yu J, Sun Z. The Impact of COVID-19 on Blood Glucose: A
Systematic Review and Meta-Analysis. Frontiers in Endocrinology. 2020;11(732).
25.   Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-
acute COVID-19 syndrome. Nature Medicine. 2021;27(4):601-15.
26.   Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, et al. Proteomic and Metabolomic
Characterization of COVID-19 Patient Sera. Cell. 2020;182(1):59-72 e15.
27.   Senn S, editor Dichotomania: An Obsessive Compulsive Disorder that is Badly Affecting
the Quality of Analysis of Pharmaceutical Trials2005.
28.   Roozenbeek B, Lingsma HF, Perel P, Edwards P, Roberts I, Murray GD, et al. The
added value of ordinal analysis in clinical trials: an example in traumatic brain injury. Crit Care.
2011;15(3):R127.
29.   Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al.
Attributes and predictors of long COVID. Nature Medicine. 2021;27(4):626-31.
30.   Arunachalam PS, Wimmers F, Mok CKP, Perera RAPM, Scott M, Hagan T, et al.
Systems biological assessment of immunity to mild versus severe COVID-19 infection in
humans. Science. 2020;369(6508):1210-20.
31.   Overmyer KA, Shishkova E, Miller IJ, Balnis J, Bernstein MN, Peters-Clarke TM, et al.
Large-Scale Multi-omic Analysis of COVID-19 Severity. Cell Systems. 2021;12(1):23-40.e7.
32.   Su Y, Chen D, Yuan D, Lausted C, Choi J, Dai CL, et al. Multi-Omics Resolves a Sharp
Disease-State Shift between Mild and Moderate COVID-19. Cell. 2020;183(6):1479-95.e20.
33.   Schenck EJ, Hoffman KL, Cusick M, Kabariti J, Sholle ET, Campion TR. Critical carE
Database for Advanced Research (CEDAR): An Automated Method to Support Intensive Care
Units with Electronic Health Record Data. J Biomed Inform. 2021:103789.
34.   Goncalves MD, Hwang SK, Pauli C, Murphy CJ, Cheng Z, Hopkins BD, et al.
Fenofibrate prevents skeletal muscle loss in mice with lung cancer. Proc Natl Acad Sci U S A.
2018;115(4):E743-e52.
35.   Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating
viruses and cellular organisms. Nucleic Acids Res. 2021;49(D1):D545-d51.
36.   Dieterle F, Ross A, Schlotterbeck G, Senn H. Probabilistic quotient normalization as
robust method to account for dilution of complex biological mixtures. Application in 1H NMR
metabonomics. Anal Chem. 2006;78(13):4281-90.
37.   Do KT, Wahl S, Raffler J, Molnos S, Laimighofer M, Adamski J, et al. Characterization of
missing values in untargeted MS-based metabolomics data and evaluation of missing data
handling strategies. Metabolomics. 2018;14(10):128.
38.   Chetnik K, Benedetti E, Gomari DP, Schweickart A, Batra R, Buyukozkan M, et al.
maplet: An extensible R toolbox for modular and reproducible omics pipelines2021 May 01,

2021:[arXiv:2105.04305 p.]. Available from:
https://ui.adsabs.harvard.edu/abs/2021arXiv210504305C.
39.   Schäfer J, Strimmer K. A shrinkage approach to large-scale covariance matrix
estimation and implications for functional genomics. Stat Appl Genet Mol Biol. 2005;4:Article32.
40.   Prim RC. Shortest Connection Networks And Some Generalizations. Bell System
Technical Journal. 1957;36(6):1389-401.
41.   McCullagh P. Regression Models for Ordinal Data. Journal of the Royal Statistical
Society Series B (Methodological). 1980;42(2):109-42.
42.   Ripatti S, Palmgren J. Estimation of multivariate frailty models using penalized partial
likelihood. Biometrics. 2000;56(4):1016-22.
43.   Therneau T. Coxme and the Laplace approximation 2020 [Available from: https://cran.r-
project.org/web/packages/coxme/vignettes/laplace.pdf.
588
589

Fig. 1. Study outline. Study population composed by COVID-19 patients and controls. Serum samples obtained from clinically indicated specimens during the first 72 hours of admission. Metadata obtained from electronic medical records. We obtained metabolomic and proteomic profile, after which we integrated our findings into a single network describing the associations between differentially expressed proteins and metabolites in COVID-19. We then correlated the metabolites and proteins with baseline characteristics, laboratory parameters and clinical events. Finally, we developed a novel metabolite-based prediction model for a composite outcome measure comprised of key clinical parameters including death, mechanical ventilation, initiation of dialysis, supplemental oxygen requirement, development of acute kidney injury, and length of hospital stay.

Fig. 2. Metabolomics and Proteomics changes associated with COVID-19. A, Volcano plot
showing differentially expressed metabolites between COVID-19 patients and controls at an
adjusted p-value <0.05. In red, upregulated metabolites in COVID-19 patients. In blue,
upregulated metabolites in the control group. **B,** Top 3 differentially expressed metabolites in
COVID-19 patients vs. controls based on adjusted p-value. **C,** Bar plot representing the main
KEGG metabolic pathways altered in COVID-19 based on the previous results. **D,** Volcano plot
showing the differentially expressed proteins between COVID-19 patients and controls at an
adjusted p-value <0.05. **E,** Top 3 differentially expressed proteins in COVID-19 patients vs.
controls based on adjusted p-value. **F,** Bar plot representing the main altered protein-based
KEGG signaling pathways altered in COVID-19 based on the previous results.
615

A

	Protein
○	Metabolite
■	Significant
□	Non-significant

B

JAM-A

GRN TR   MCP-2   4-Hydroxyproline

MCP-1   MCP-3   IL6

                                                          TRANCE

Caprylic acid   Cytosine   PD-L1

                                      Mod. 3   MMP12

Fumaric acid   MERTK

L-Tryptophan   Mod. 2   TM

                                    RAGE   D-Glucose

Orotic acid   Niacinamide

IL-1ra   Mod. 4   Glycerol 3-phosphate

D-2-Hydroxyglutaric   CTSD

acid   Guanidoacetic acid

Argininosuccinic   L-Proline

acid   TNFSF13B   Betaine

Hexanoylcarnitine   CCL24

CXCL11   L-Cystathionine

                    Gal-9   BOC

CXCL10   L-Kynurenine

IFN-gamma   Mod. 1

                          Arachidonic acid

MMP7   Hypoxanthine

CCL17   L-Leucine

                    Pyroglutamic acid   L-Lactic acid   Oxoglutaric acid   CSF-1

3-Hydroxybutyric acid   Creatine

L-Carnitine   5-Methyladenosine

                    Gluconolactone

                    Acetylcholine

ADA

■	Inflammation
■	Vascular injury
●	Metabolite

Fig. 3. Protein-metabolite networks in COVID-19. A, Gaussian graphical model (GGM)

representing the significant partial correlations between all the measured metabolites and proteins.

Circles indicate metabolites and squares indicate proteins. The differentially expressed molecules

between COVID-19 patients and controls are highlighted in gray. **B,** Simplified version of the

GGM network using minimum spanning (MST) algorithm combined with a shortest paths-based

approach, including all the differentially expressed metabolites and proteins between COVID-19

patients and controls. Squares indicate proteins and green circles indicate metabolites.

Inflammatory proteins are colored in purple, while vascular injury proteins are colored in red.

Shadows represent molecule modules.

Fig. 5. Metabolomics signature predicts clinical outcomes of COVID-19. A, Scheme of the hierarchical composite outcome ranging from in-hospital mortality to length of hospital stay and disposition (MV: Mechanical ventilation, KRT: Kidney replacement therapy). **B,** Dot plot comparing the predictive performance (Concordance index) of a baseline model using age, sex, and BMI and a model including baseline plus metabolites. The results show that the prediction accuracy improves when adding metabolites to the model. **C,** Bar plot showing the main altered metabolic groups included in the composite outcome score. **D,** Dot plots showing individual outcome analysis, comparing the baseline model and baseline plus metabolites added. Metabolites improve the prediction accuracy of ARDS, AKI, supplemental oxygen requirement and prolonged hospitalization.

Characteristic	Negative, N = 97[1]	COVID-19, N = 330[1]	p-value[2]
Demographics			
Age	64 (51, 77)	64 (52, 75)	0.8
Sex			**0.017**
Female	48 (49%)	117 (35%)	
Male	49 (51%)	213 (65%)	
Race			**<0.001**
Asian	10 (10%)	24 (7.3%)	
Black	15 (15%)	40 (12%)	
Not specified	16 (16%)	48 (15%)	
Other	6 (6.2%)	71 (22%)	
White	50 (52%)	147 (45%)	
BMI	24.7 (21.7, 28.5)	27.4 (23.7, 31.0)	**<0.001**
Risk Factors			
CAD	23 (24%)	55 (17%)	0.2
DM	19 (20%)	89 (27%)	0.2
HTN	55 (57%)	182 (55%)	0.9
CKD/ESRD	17 (18%)	17 (5.2%)	**<0.001**
Active cancer	40 (41%)	30 (9.1%)	**<0.001**
Immunosuppressed state	29 (30%)	14 (4.2%)	**<0.001**
Laboratories			
Lymphocyte count	1.03 (0.50, 1.60)	0.80 (0.60, 1.10)	0.081
Platelet count	202 (132, 275)	191 (145, 252)	0.9
D-dimer	242 (150, 555)	386 (242, 667)	0.2
Alanine aminotransferase	22 (14, 40)	35 (23, 54)	**<0.001**
Aspartate aminotransferase	25 (19, 38)	40 (28, 61)	**<0.001**
Ferritin	727 (147, 1167)	769 (358, 1449)	0.4
C-reactive protein	3 (1, 7)	11 (6, 19)	**0.006**
Procalcitonin	0.43 (0.13, 1.06)	0.17 (0.08, 0.42)	**0.007**
Clinical Outcomes			
Acute Kidney Injury (AKI) stage			**<0.001**
0	89 (92%)	214 (65%)	
1	4 (4.1%)	43 (13%)	
2	0 (0%)	16 (4.8%)	
3	4 (4.1%)	42 (13%)	
Kidney replacement therapy	7 (7.2%)	26 (7.9%)	>0.9
Acute respiratory failure requiring intubation	11 (11%)	103 (31%)	**<0.001**
Thromboembolic event	6 (6.2%)	22 (6.7%)	>0.9
In-hospital mortality	13 (13%)	56 (17%)	0.6

[1] Statistics presented: median (IQR); n (%)

[2] Statistical tests performed: Wilcoxon rank-sum test; chi-square test of independence; Fisher's test with simulated p-value; Fisher's exact test

653